Get started
Author

Hugo Calderón

Observed names: Calderon, Hugo, H Calderón, Hugo Calderon
Observed institutions: Hospital Sant Joan de Déu Barcelona, University of Oxford, PsiOxus Therapeutics (United Kingdom), Hospital Clínic de Barcelona, Fundació Clínic per a la Recerca Biomèdica, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona
ORCID: 0000-0002-8902-4302
Observed ORCID: 0000-0002-8902-4302
OpenAlex ID: A5053189242
Engineering and Design of Chimeric Antigen Receptors
2018 · Sonia Guedan, Hugo Calderon, et al. · Molecular Therapy — Methods & Clinical Development · 453
PDF
Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field
2014 · Dragomira Majhen, Hugo Calderon, et al. · Human Gene Therapy · 102
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
2024 · Irene Andreu-Saumell, Alba Rodriguez-Garcia, et al. · Nature Communications · 78
PDF
Analysis of CAR-Mediated Tonic Signaling
2019 · Hugo Calderon, Maksim Mamonkin, et al. · Methods in molecular biology · 63
Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
2016 · Arthur Dyer, Ying Di, et al. · Molecular Therapy — Oncolytics · 49
PDF
Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes
2017 · Nalini Marino, Sam Illingworth, et al. · PLoS ONE · 31
PDF
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
2025 · Anna De Lucia, Lucia Mazzotti, et al. · Frontiers in Immunology · 23
PDF
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections
2023 · Natalia Egri, Hugo Calderón, et al. · Frontiers in Immunology · 18
PDF
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction
2016 · L A Rojas, R Moreno, et al. · Cancer Gene Therapy · 13
A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry
2025 · Juan José Mata-Molanes, Leticia Alserawan, et al. · Pharmaceutics · 7
CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood
2022 · Natalia Egri, Victoria Olivé, et al. · Frontiers in Immunology · 6
PDF
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial
2026 · Valentín Ortiz-Maldonado, Núria Martínez-Cibrian, et al. · The Lancet Haematology · 5
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS ‐ CoV ‐2 in Exposed Individuals From Emilia Romagna Region and COVID ‐19 Severity
2025 · Lucia Mazzotti, Patricia Borges de Souza, et al. · HLA · 5
PDF
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model
2025 · Aina Oliver-Caldes, Joan Mañe Pujol, et al. · OncoImmunology · 4
PDF
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al. · Cancer Immunology Research · 4
Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches
2024 · Daouda Abba Moussa, Mario Vazquez, et al. · Emerging Microbes & Infections · 4
PDF
Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
2025 · Núria Martínez‐Cibrián, Valentín Ortiz‐Maldonado, et al. · HemaSphere · 3
PDF
Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
2022 · Luis Gerardo Rodríguez-Lobato, Oriol Cardus, et al. · Blood · 1
What will (and should) be improved in CAR immunotherapy?
2022 · Europa Azucena González-Navarro, Marta Español, et al. · International review of cytology · 1
Evaluation of Enadenotucirev (ColoAd1), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with chemotherapeutic agents in a murine model of ovarian cancer
2014 · Sam Illingworth, Hugo Calderón, et al. · Human Gene Therapy · 1
Context-dependent tonic signaling shapes the performance and manufacturability of a 4-1BB–based HER2 CAR-T cell therapy
2026 · Laura Angelats, Berta Marzal, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract C007: A versatile microRNA-based platform for activation-dependent regulation of armored CAR T cell payloads
2026 · Nina Barceló-Genestar, Teresa Lobo-Jarné, et al. · Cancer Immunology Research
Supplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Works count: 44
Citation count: 887
H-index: 10
I10-index: 10
Year
Topic
Type